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ABSTRACT 
The liver X receptors Lxrα/NR1H3 and 
Lxrβ/NR1H2 are ligand-dependent nuclear receptors 
critical for midbrain dopaminergic (mDA) neuron 
development. We previously found that 24(S),25-
epoxycholesterol (24,25-EC), the most potent and 
abundant Lxr ligand in the developing mouse 
midbrain, promotes mDA neurogenesis in vitro. In 
this study, we demonstrate that 24,25-EC promotes 
mDA neurogenesis in an Lxr-dependent manner, in 
the developing mouse midbrain in vivo and also 
prevents toxicity induced by the Lxr inhibitor 
geranylgeranyl pyrophosphate. Furthermore, using 
MS we show that overexpression of human 
cholesterol 24S-hydroxylase (CYP46A1) increases 
the levels of both 24(S)-hydroxycholesterol (24-HC) 
and 24,25-EC in the developing midbrain, resulting 
in a specific increase in mDA neurogenesis in vitro 
and in vivo, but has no effect on occulomotor or red 
nucleus neurogenesis. 24-HC, unlike 24,25-EC, did 
not affect in vitro neurogenesis, indicating that the 
neurogenic effect of 24,25-EC on mDA neurons is 
specific. Combined, our results indicate that 
increased levels of 24,25-EC in vivo, by 
intracerebroventricular delivery in wild-type mice or 
by overexpression of its biosynthetic enzyme 
CYP46A1, specifically promote mDA neurogenesis. 
We propose that increasing the levels of 24,25-EC in 
vivo may be a useful strategy to combat the loss of 
mDA neurons in Parkinson’s disease. 
 
 
 
The vertebrate CNS is composed of an 
extensive variety of neurons that are generated 
following tightly-regulated developmental programs. 
Characterization of the function and specificity of 
molecules selectively controlling distinct neuronal 
populations is thus essential in order to enhance our 
understanding of how such complexity is achieved in 
the developing brain, how it is maintained in the 
adult brain and how it can be used for therapeutic 
 http://www.jbc.org/cgi/doi/10.1074/jbc.RA118.005639The latest version is at 
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purposes. Specific nuclear hormone receptors and 
their ligands have been identified as crucial factors in 
these processes (1, 2, 3). We have previously shown 
that liver X receptors (Lxrα and Lxrβ, encoded by 
NR1H3 and NR1H2, respectively) and their 
endogenous brain ligands (oxidized derivatives of 
cholesterol and related molecules) regulate the 
development of midbrain dopamine (mDA) neurons 
(4, 5, 6), red nucleus neurons (5), as well as 
oculomotor neurons (7). Moreover, enzymes 
involved in the biosynthesis of cholesterol, oxysterols 
and 24(S),25-epoxycholesterol (24,25-EC), such as 
2,3-oxidosqualene-lanosterol cyclase (OSC), 
Cytochrome P450 family 11 subfamily A member 1 
(CYP11A1) and CYP46A1 (also known as 
cholesterol 24S-hydroxylase), are expressed in the 
developing mouse ventral midbrain (VM) during VM 
neurogenesis (4, 8, 9, 10). The enzyme CYP46A1 
oxidises cholesterol to 24(S)-hydroxycholesterol (24-
HC), the most abundant oxysterol in the adult brain, 
present at 20-40 ng/mg levels in mouse and human 
(11). It has been shown in vitro in human kidney 
HEK293 cells transfected with CYP46A1 that 24-HC 
can be further oxidized to 24,25-
dihydroxycholesterol (24,25-diHC) and to 24,27-
diHC (systematic name 24,26-diHC, ref. 12) by 
CYP46A1 (13, 14). It is suggested by these studies 
that 24,25-diHC could then be converted to 24,25-
EC, but definite evidence for such a mechanism is 
lacking. Interestingly, it has been shown in vitro that 
CYP46A1 can also oxidise desmosterol to 24,25-EC 
and to 27-hydroxydesmosterol (systematic name 26-
hydroxydesmosterol) (15), thereby providing a 
distinct 24,25-EC biosynthetic pathway via 
desmosterol in the brain. In agreement with this 
study, there is a reduction in both 24-HC and 24,25-
EC levels in Cyp46a1-knockout mouse adult brain 
compared to wild-type brain (16). An alternative 
route to 24,25-EC formation is via a shunt of the 
mevalonate pathway, specifically the Bloch arm of 
the pathway, in which an extra oxygen atom is 
introduced by squalene epoxidase into 3S-squalene-
2,3-epoxide to give squalene-2,3(S);22(S),23-
diepoxide prior to cyclisation by OSC (17). This 
pathway is also expected to be impaired in the 
Cyp46a1-knockout mouse as the necessary enzymes 
are down regulated as a consequence of reduced 
cholesterol biosynthesis (18).    
The functions of 24-HC and 24,25-EC in the 
CNS are diverse. 24-HC plays a role as a cholesterol 
transport molecule, crossing the blood brain barrier 
and thus facilitating transport of cholesterol to the 
liver for further metabolism (8, 11, 19). 24-HC is also 
a ligand for Lxrα and Lxrβ in the brain (5) and binds 
to the endoplasmic reticulum resident protein INSIG 
(insulin-induced gene) (20), modulating the 
processing of SREBP-2 (sterol response element-
binding protein-2), to its active form as the master 
transcription regulator for cholesterol biosynthesis. 
On the other hand, 24,25-EC is the most abundant 
Lxr ligand in the developing, but not in the adult 
brain (5, 21). Within the embryonic VM, 24,25-EC is 
present at a much higher concentration than 24-HC 
(ref. 5 and present study). Moreover, we previously 
found that 24,25-EC is the most potent endogenous 
Lxr ligand at promoting mDA neurogenesis in both 
mouse progenitor VM cultures, embryonic stem cells 
in vitro and in zebrafish in vivo (5). However, the 
function of 24,25-EC in the developing mouse brain 
in vivo remains to be determined. In this study we 
address this question by examining the midbrain of 
mouse embryos either intracerebroventricularly 
injected with 24,25-EC in utero or transgenic mice 
expressing CYP46A1 under the control of a hybrid 
beta-actin promoter (22). We show that increases in 
24,25-EC in the developing VM, by either of these 
two strategies, result in increased number of mDA 
neurons in vivo. Thus, our results identify a new 
function of CYP46A1 and 24,25-EC in the 
mammalian brain in vivo. 
 
 
Results 
CYP46A1-overexpressing mice exhibit elevated 
levels of 24-HC and 24,25-EC 
In order to examine the role of CYP46A1 in 
the developing brain, we examined the VM of 
transgenic mice overexpressing this enzyme. We first 
analyzed the levels of several sterols, oxysterols and 
related compounds in wild-type and CYP46A1-
overexpressing mice. We found a 29.2-fold increase 
in 24-HC levels and a 3.9-fold increase in 24,25-EC 
levels in the developing VM of CYP46A1-
overexpressing mice compared to wild-type mice at 
E11.5 (Fig. 1 and Table S1). We also found a 1.98-
fold increase in cholesterol levels in the developing 
VM of CYP46A1-overexpressing mice compared to 
wild-type mice (Table S1). However, the level of 
desmosterol (266-fold higher than that of 24,25-EC 
in wild-type mice) did not change in CYP46A1-
overexpressing mice. Furthermore, we did not find 
any alteration in 22(R)-HC, 25-HC, 27-HC 
(systematic name (25R)26-HC), 7α-HC or 7α,24-
dihydroxycholesterol in CYP46A1-overexpressing 
mice (Table S1), indicating that the increases in 24-
HC and 24,25-EC levels are very specific. 
To determine whether these changes were 
stable over time, we analyzed the levels of these 
compounds in the adult brain of CYP46A1- 
overexpressing mice. We found that, while the levels 
of cholesterol were not significantly different from 
wild-type mice, the levels of 24-HC and 24,25-EC 
increased by 22% and 25% respectively in CYP46A1-
overexpressing mice (Table S2). Thus, our results 
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portend CYP46A1 as a highly-relevant enzyme in the 
biosynthesis of 24,25-EC in the developing and adult 
mouse brain. 
Interestingly, our analysis of the developing 
mouse VM by single cell RNA-sequencing (10), 
indicate that Cyp46a1 is expressed at higher levels in 
two cell types lining the ventricle, ependymal and 
radial glia-like3 cells (Fig. S1), suggesting that these 
cell types may be the endogenous source of 24-HC 
and 24,25-EC in the developing VM. 
 
Increased dopamine neuron number in midbrain 
cultures from CYP46A1-overexpressing mice  
We next studied the impact of CYP46A1-
overexpression on distinct neuronal populations in 
the developing VM. Notably, mouse VM progenitor 
cultures from CYP46A1-overexpressing mice 
exhibited a significant 49.8% increase in the number 
of mDA neurons compared to cultures from wild-
type mice (Fig. 2A and 2B). These neurons co-
expressed the rate-limiting enzyme in the synthesis of 
dopamine, Tyrosine Hydroxylase (TH), beta III 
Tubulin (TuJ1, a pan-neuronal marker), Forkhead 
box transcription factor (Foxa2), required for 
midbrain development regulation (23) and Pituitary 
homeobox 3 (Pitx3), a transcription factor required 
for the survival and maintenance of mDA neurons 
(24) (Fig. 2A), thereby showing that they were true 
mDA neurons. Since mouse Cyp46a1 was also 
expressed in other cell types of the developing VM 
(Fig. S1), we examined adjacent neuronal 
populations. No significant change in the number of 
Islet1+ occulomotor neurons or of Brn3a+ red nucleus 
neurons was detected (Fig. 2B), thereby 
demonstrating that the effect of CYP46A1 
overexpression is specific to mDA neurons. We next 
examined whether 24-HC or 24,25-EC increase the 
number of mDA neurons when added to wild type 
VM progenitor cultures. While 24,25-EC enhances 
mDA neurogenesis (ref. 5 and Fig. S2), we found that 
24-HC had no significant effect on the number of 
TH+ mDA neurons (Fig. S3). Interestingly, the effect 
of 24,25-EC on TH+ mDA neurons was abolished in 
VM progenitor cultures from Lxrαβ double knockout 
mice (Fig. S2), thereby showing that LXR receptors 
are required for the increase of mDA neuron numbers 
by 24,25-EC. Combined, our results indicate that 
elevated levels of 24,25-EC lead to increased number 
of mDA neurons in CYP46A1-overexpressing mice. 
 
CYP46A1-overexpression increases the number of 
mDA neurons in the developing brain in vivo  
We also investigated whether CYP46A1-
overexpression does impact VM development in vivo. 
We thus examined the number of mDA and 
occulomotor neurons in coronal sections through the 
VM of CYP46A1-overexpressing and wild-type mice 
at E11.5. We observed that the number of TH+ mDA 
neurons significantly increased by 42.6% in 
CYP46A1-overexpressing compared to wild-type 
mice (Fig. 3A and 3B). However, the number of 
Islet1+ occulomotor neurons did not change, arguing 
for a specific effect of CYP46A1-overexpression on 
mDA neurons in vivo. Combined, our results indicate 
that elevated levels of 24,25-EC in CYP46A1-
overexpressing mice lead to increased number of 
mDA neurons. 
 
24,25-EC promotes mouse midbrain dopaminergic 
neurogenesis in vivo and prevents toxicity by GGPP 
Finally, in order to directly examine the 
function of 24,25-EC in the developing mouse 
midbrain in vivo, we performed 24,25-EC injections 
into the cerebrospinal fluid, at the level of the 
aqueduct, in E11.5 wild-type mouse embryos in utero 
and analyzed brain sections at the midbrain level at 
E13.5 (Fig. 4A). Neurogenesis was examined by 
performing a pulse of EdU intraperitoneally at E11.5, 
to label proliferative progenitors and assess their 
capacity to undergo neurogenesis and give rise to 
mDA neurons that can be identified by the expression 
of tyrosine hydroxylase (Th). Upon injection of 
24,25-EC, we found that the number of double 
EdU+;TH+ cells increased by 39% (Fig. 4B and 4C), 
thereby demonstrating that 24,25-EC promotes mDA 
neurogenesis in vivo. In contrast, injection of the Lxr 
inhibitor geranylgeranyl pyrophosphate (GGPP), 
reduced the number of double EdU+;TH+ cells, 
indicating that LXR activity is required for mDA 
neuron development. Notably, the effect of GGPP 
was blocked by co-injection of 24,25-EC, indicating 
that 24,25-EC is not only required and sufficient to 
promote mDA neurogenesis in vivo, but can also 
prevent the toxic effect of GGPP. Thus, our results 
demonstrate that elevated levels of 24,25-EC promote 
mDA neurogenesis in vivo. 
 
 
Discussion 
In this study we show that overexpression of 
CYP46A1 in transgenic mice increases the levels of 
24-HC and 24,25-EC in the VM, but does not alter 
desmosterol or other oxysterol levels, which remain 
at a similar level as in wild-type mice. Our results, 
together with previous findings showing a reduction 
in both 24-HC and 24,25-EC levels in Cyp46a1-
knockout mice (16), lend support to the hypothesis 
that CYP46A1 is highly-relevant in the biosynthesis 
of 24,25-EC. This could be achieved either by 
increased biosynthesis of 24,25-EC from desmosterol 
by CYP46A1 (as suggested in ref. 15), or by 
increased biosynthesis of 24,25-EC from cholesterol 
by CYP46A1 via 24-HC and 24,25-diHC (as 
suggested in ref. 13 and 14). In either case, our 
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results demonstrate the importance of CYP46A1 in 
24,25-EC biosynthesis in the developing mammalian 
VM. We also found that 24-HC does not affect the 
number of mDA neurons, whereas 24,25-EC strongly 
promotes mDA neurogenesis, a finding consistent 
with our previous results showing Lxr ligand-specific 
activities in the developing mouse VM (5, 7). These 
results also indicate that the observed increase in 
mDA neurogenesis in vitro and in vivo, in CYP46A1-
overexpressing mice, is indeed associated with the 
increase in 24,25-EC in these mice. Notably, the 
effect of CYP46A1 was specific to mDA neurons, as 
neighboring cell populations in the developing basal 
plate of the VM, such as occulomotor neurons or red 
nucleus neurons, were not affected in CYP46A1-
overexpressing mice. These results show that 
increased levels of Lxr ligands do not alter their cell 
type specificity, which is conferred by LXRs, as we 
previously described (5, 7). Mechanistically, we 
found that intracerebroventricular injection of the 
LXR agonist, 24,25-EC, or the LXR antagonist 
GGPP, were capable of respectively promoting or 
inhibiting mDA neurogenesis in vivo. These effects 
were specific since 24,25-EC had no effect on red 
nucleus, serotonin+ neurons, oculomotor neurons, or 
γ-aminobutyric acid+ (GABA+) neurons in vitro and 
in vivo (ref. 5 and present results). In sum, our results 
demonstrate a clear role of LXR receptors and 24,25-
EC in mDA neurogenesis in vivo.  
Several studies have associated a reduced 
level of CYP46A1 with neurodegeneration and 
neuronal dysfunction, as well as restoration of normal 
CYP46A1 levels with functional recovery and 
neuroprotection. For instance, knock-down of 
Cyp46a1 in mice results in deficits in spatial, 
associative, and motor learning, and in hippocampal 
long-term potentiation (25). In addition, reduced 
Cyp46a1 levels result in cognitive deficits, elevated 
production of amyloid-beta peptides and abnormal 
phosphorylation of tau (26), as well as in progressive 
loss of hippocampal neurons and an Alzheimer's 
disease-like phenotype (27). Conversely, increased 
expression of CYP46A1 improves spatial memory 
retention in aged female mice (28) and reduces 
cognitive decline and amyloid burden in several 
mouse models of Alzheimer's disease (29, 30, 31). 
Furthermore, similar results have been obtained by 
enhancing CYP46A1 activity with the reverse 
transcriptase inhibitor, efavirenz (32), arguing for the 
feasibility of using a pharmacological treatment to 
reduce neurodegeneration. 
With regard to neurodegeneration in the 
basal ganglia, it has been reported that the level of 
CYP46A1 is decreased in the putamen of patients 
with Huntington’s disease (33). Notably, CYP46A1 
knock-down in the mouse striatum induced 
spontaneous striatal neurodegeneration associated 
with abnormal balance and motor coordination. 
Conversely, increased levels of CYP46A1 in the 
R6/2 Huntington’s disease mouse model, decreased 
striatal neuron atrophy, protein aggregates and motor 
deficits.  
Much less is known about the role of 
CYP46A1 in Parkinson’s disease. For instance, it 
remains to be determined whether the level and 
functionality of CYP46A1 are conserved or altered in 
Parkinson’s disease models or patients. The results 
presented in this study provide first evidence that 
24,25-EC can rescue a defect in mDA neurogenesis 
induced by GGPP in vivo, suggesting a potential 
application of CYP46A1 and 24,25-EC in 
regenerating mDA neurons in vivo. Previous studies 
have also shown that a synthetic LXR ligand can 
prevent the degeneration of mDA neurons in an 
animal model of Parkinson’s disease (34). Thus 
combined, our results and data in the literature 
suggest that 24,25-EC or pharmacological tools 
capable of activating LXR receptors or enhancing the 
function and/or levels of CYP46A1 could be used to 
enhance mDA neurogenesis, limit neurodegeneration 
and advance cell replacement strategies for the 
treatment of Parkinson’s disease.  
 
 
 
Experimental Procedures 
Extraction of Sterols  
Sterols were extracted from mouse adult 
brain and mouse embryonic VM into ethanol and 
fractionated by reversed phase solid phase extraction 
(SPE) to give an oxysterol rich fraction devoid of 
cholesterol (5, 7, 16, 36). 
 
Charge-Tagging of Sterols 
The sterols were charge-tagged with the GP-
hydrazine as described previously (5, 7, 16, 36). This 
greatly enhances their response when analysed by 
liquid chromatography - electrospray ionization – 
mass spectrometry (LC-ESI-MS) and -mass 
spectrometry with multistage fragmentation (MSn).  
 
Reagents 
HPLC grade water and solvents were from 
Fisher Scientific (UK) or Sigma Aldrich (UK). 
Authentic sterols and oxysterols were from Avanti 
Polar Lipids (Alabama, USA). Girard P (GP) reagent 
(1-[carboxymethyl]pyridinium chloride hydrazide, 
[2H0]GP) was from TCI Europe (UK) or synthesized 
in-house ([2H5]GP) as in earlier studies (37), and 
cholesterol oxidase from Streptomyces sp was from 
Sigma-Aldrich. Certified Sep-Pak C18
 
200 mg (SPE1) 
and OASIS HLB 60 mg (SPE2) columns were from 
Waters (UK). 
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LC-ESI-MSn on the Orbitrap ELITE 
LC-ESI-MS and LC-ESI-MSn were 
performed using an Ultimate 3000 HPLC system 
(Dionex, now ThermoFisher Scientific, UK) linked to 
the ESI source of an Orbitrap ELITE (Thermo Fisher 
Scientific, CA) mass spectrometer as described 
previously (5, 7, 16, 35, 36). 
 
Wild-type mice 
Mice were housed, bred, and treated 
according to the guidelines of the European 
Communities Council (directive 86/609/EEC) and the 
Society for Neuroscience (www.sfr.org/handbook). 
Ethical approval for mice experimentation was 
granted by Stockholm Norra Djurförsöksetisks 
Nämnd number N154/06, N145/09, N370/09, 
N273/11 and N486/12. 
 
Mice overexpressing human CYP46A1 
Human CYP46A1-overexpressing transgenic 
mice were generated as described before (22, 28). All 
animal experiments received full approval from the 
local Animal Experimentation Ethics Committee. 
Tissue sampling from these mice was performed 
under the aegis of the UK Scientific Procedures 
(Animals) Act, 1986. 
 
Primary midbrain cultures 
 Brains from E11.5 mice were obtained, the 
ventral midbrain region was dissected, mechanically 
dissociated and plated on poly-D-lysine (150,000 
cells/cm2) and grown in serum-free N2 media 
consisting of 1:1 mixture of F12 and DMEM with 10 
ng/mL insulin, 100 µg/mL apo-transferrin, 100 µM 
putrescine, 20 nM progesterone, 30 nM selenium, 6 
mg/mL glucose, and 1 mg/mL BSA. Cells were 
treated for 3 days in vitro (DIV) with the compounds 
of interest, fixed with 4% PFA and processed for 
staining using appropriate antibodies. Hoechst 
staining was performed by permeabilizing cells with 
a 0.3% Triton-X 100/PBS solution for 5 min 
followed by incubation with Hoechst 33258 (Sigma) 
for 10 min. 
 
Immunocytochemical analysis 
 Cells were fixed in 4% paraformaldehyde 
(PFA), washed in PBS and blocked in 5% normal 
goat serum/PBS for 1 h at room temperature. 
Primary antibodies were diluted in PBS (pH 7.4), 
0.3% Triton X-100, 1% BSA and incubations were 
carried out overnight at +4°C or at room temperature 
for 2 h. The antibodies used were: anti-TH (1:1000; 
Pel-Freeze), anti-Islet-1 (1:100; Developmental 
Studies Hybridoma Bank), anti-Brn3a (1:250; 
Millipore), anti-TuJ1 (1:1,000; Promega), anti-
FoxA2 (1:400; Cell Signaling Technology), anti-
Pitx3 (1:400; Invitrogen) and appropriate secondary 
antibodies (Jackson ImmunoResearch or Alexa). 
Cells positive for the corresponding marker were 
counted directly at the microscope at a magnification 
of 20×. Cells were counted in every well, in eight 
consecutive fields (going from one side of the well to 
the other, passing through the center), in three 
different wells per experiment and in three different 
experiments per condition. Positive cell counts were 
normalized to total number of cells (counted utilizing 
Hoechst stained nuclei) and presented as fold 
increase over wild-type or vehicle. Random pictures 
of the wells were taken for every condition to 
document the result, and representative pictures were 
subsequently selected to represent the quantitative 
data. Photos were acquired with a Zeiss Axioplan 
microscope and a Hamamatsu camera C4742-95 
using the Openlab software.  
 
In-utero intraventricular injections 
Mouse in-utero injections were performed as 
previously described (7, 38). Female wild-type CD-1 
mice (25–35 g; Charles River Breeding Laboratories) 
were used for these experiments. Ethical approval 
was granted by Stockholm Norra Djurförsöksetisks 
Nämnd number N273/11 and N486/12. For embryo 
analyses, wild type CD-1 mice were mated overnight, 
and noon of the day the plug was considered E0.5. 
E11.5 pregnant females were deeply anesthetized 
using Isofluorane (IsoFlo®, Abbott Labs) and the 
uterine horns were accessed through an abdominal 
incision. 1 µL of 24,25-EC (5 mM), GGPP (5 mM) or 
vehicle solution (methanol/PBS, 50% v/v) was 
injected into the cerebral aqueduct. The uterine horns 
were replaced into the abdominal cavity, which was 
then closed with sutures. For EdU pulse-chase 
experiments, EdU (50 mg/kg body weight) was 
injected by intraperitoneal injection 30 mins after the 
injections to the embryo. Embryos were analyzed 48 
h later, at E13.5. The concentration and volume of 
the compounds utilized in these experiments were 
chosen in order for the compounds to be in a 
physiological range, since the CSF volume in the 
E11.5 mouse embryo is approximately 40 µl, the CSF 
is replaced at a speed of 3.3 × 10−4 ml/min in mice 
(39) and mouse embryos were analysed 48 hours 
after injection. 
 
Mouse VM coronal sections and 
immunohistochemical analysis 
Embryos were dissected out of the uterine 
horns in ice-cold PBS, fixed in 4% PFA for 4 h to 
overnight, cryoprotected in 15–30% sucrose, frozen 
in Tissue-Tek Optimum Cutting Temperature (OCT) 
compound (Sakura Fine-Tek) on dry ice, and stored 
at -80°C until use. 14 µm serial coronal sections 
through the E11.5 or E13.5 midbrain region were cut 
on a cryostat and placed serially on 10 slides. Slides 
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number 1 and 6 were subjected to 
immunohistochemistry. Sections were pre-incubated 
for 1 h in blocking solution followed by incubation at 
4°C overnight with the following primary antibodies: 
sheep anti-TH (1:500; Novus Biologicals), rabbit 
anti-TH (1:750, Pel-Freeze), mouse anti-Islet-1 
(1:100; Developmental Studies Hybridoma Bank). 
After washing, slides were incubated for 1 h at room 
temperature with the appropriate fluorophore-
conjugated (Cy2-, Cy3-and Cy5-, 1:300, Jackson 
Laboratories; Alexa488-, 555-, and 647-, 1:1000, 
Invitrogen) secondary antibodies. EdU click reaction 
was performed according to instructions of the 
manufacturer (Life Technologies). Confocal pictures 
were taken on a Zeiss LSM700 microscope.  The 
numbers of TH+ cells, Islet1+ cells and double 
EdU+;TH+ cells, were counted on 3 sections covering 
from rostral to caudal midbrain for each embryo. 
 
Statistical Analysis 
 Statistical analyses (Mann-Whitney test and 
Student’s t-test) were performed using Prism 4 
(GraphPad Software, La Jolla, CA; 
http://www.graphpad.com). A P value less than 0.05 
was considered significant. P < 0.05 (*), P < 0.01 
(**). Data represent mean ± SEM. 
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FOOTNOTES 
The abbreviations used are: 24,25-EC, 24(S),25-epoxycholesterol; 24-HC, 24(S)-hydroxycholesterol; CYP46A1, 
Cytochrome P450 family 46 subfamily A member 1; GGPP, geranylgeranyl pyrophosphate; GP, Girard P; LC-ESI-
MS, liquid chromatography-electrospray ionization-mass spectrometry; MSn, MS/MS or MS/MS/MS, MS with 
multistage fragmentation; Lxr, Liver X receptor; mDA, midbrain dopamine; TH, tyrosine hydroxylase; VM, ventral 
midbrain. 
 
 
 
FIGURE LEGENDS 
 
Figure 1. CYP46A1-overexpressing mice exhibit elevated levels of 24,25-EC and 24-HC.  
LC-MS(MSn) analysis demonstrated a significant increase in 24,25-EC and 24-HC, but not desmosterol, 
concentrations in the developing VM of CYP46A1-overexpressing mice compared to wild-type (WT) mice. Data 
are means ± SEM (n = 4-6), * P < 0.05 by Mann-Whitney test, compared to WT group.  
 
Figure 2. Increased dopamine neuron number in midbrain cultures from CYP46A1-overexpressing mice.  
(A) Representative images of TH+ and TuJ1+ neurons, as well as Foxa2+, Pitx3+, Islet1+ and Brn3a+ neuron nuclei in 
VM cultures from wild-type and CYP46A1-overexpressing mice. Scale bar, 50 µm. (B) Quantification of TH+, 
Islet1
+
 and Brn3a+ neurons in VM cultures from wild-type and CYP46A1-overexpressing mice. Data are means ± 
SEM (n = 3), * P < 0.05 by Student’s t-test, compared to WT group. 
 
Figure 3. Increased dopamine neuron number in the VM of CYP46A1-overexpressing mice.  
(A) Representative images of anterior-to-posterior coronal VM sections from E11.5 wild-type and CYP46A1-
overexpressing mice showing TH
+
 neurons, Islet1
+ 
neuron nuclei and DAPI-stained nuclei. Scale bar, 50 µm.  
(B) Quantification of TH+ and Islet1+ neurons in VM sections from wild-type and CYP46A1-overexpressing mice. 
Data are means ± SEM (n = 5-15), * P < 0.05 by Mann-Whitney test, compared to WT group.  
 
Figure 4. 24,25-EC promotes neurogenesis of mouse midbrain dopamine neurons in vivo and prevents 
toxicity by GGPP.  
(A) Vehicle or 24,25-EC and/or GGPP were injected into the mesencephalic ventricle of E11.5 mouse embryos in 
utero, and embryos were collected at E13.5. Dopamine neurogenesis was examined by EdU intraperitoneal 
injection and by assessing the acquisition of tyrosine hydroxylase (TH) expression. (B) Quantification of double 
EdU+;TH+ cell numbers (mean ± SEM) for the indicated conditions: vehicle, 24,25-EC, GGPP, and 24,25-EC + 
GGPP injected embryos. Data are means ± SEM (n = 3-12), * P < 0.05, ** P < 0.01 by Mann-Whitney test, 
compared to vehicle group or as indicated. (C) Microphotographs of midbrain coronal sections showing TH+ 
dopamine neurons (green) and EdU+ cells (red) on the left panels and higher magnification pictures of the boxed 
region on the right panels for the indicated conditions. Arrowheads indicate double EdU+;TH+ cells. Scale bars, 50 
µm. 
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Figure 1. CYP46A1-overexpressing mice exhibit elevated levels of 24,25-EC and 24-HC.
LC-MS(MSn) analysis demonstrated a significant increase in 24,25-EC and 24-HC, but not
desmosterol, concentrations in the developing VM of CYP46A1-overexpressing mice compared to
wild-type (WT) mice. Data are means ± SEM (n = 4-6), * P < 0.05 by Mann-Whitney test,
compared to WT group.
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Figure 2. Increased dopamine neuron
number in midbrain cultures from
CYP46A1-overexpressing mice.
(A) Representative images of TH+ and
TuJ1+ neurons, as well as Foxa2+, Pitx3+,
Islet1+ and Brn3a+ neuron nuclei in VM
cultures from wild-type and CYP46A1-
overexpressing mice. Scale bar, 50 µm.
(B) Quantification of TH+, Islet1+ and
Brn3a+ neurons in VM cultures from
wild-type and CYP46A1-overexpressing
mice. Data are means ± SEM (n = 3), * P
< 0.05 by Student’s t-test, compared to
WT group.
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Figure 3. Increased dopamine neuron number in the VM of CYP46A1-overexpressing
mice. (A) Representative images of anterior-to-posterior coronal VM sections from E11.5
wild-type and CYP46A1-overexpressing mice showing TH+ neurons, Islet1+ neuron nuclei
and DAPI-stained nuclei. Scale bar, 50 µm. (B) Quantification of TH+ and Islet1+ neurons
in VM sections from wild-type and CYP46A1-overexpressing mice. Data are means ± SEM
(n = 5-15), * P < 0.05 by Mann-Whitney test, compared to WT group.
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Figure 4. 24,25-EC
promotes neurogenesis of
mouse midbrain dopamine
neurons in vivo and
prevents toxicity by GGPP.
(A) Vehicle or 24,25-EC
and/or GGPP were injected
into the mesencephalic
ventricle of E11.5 mouse
embryos in utero, and
embryos were collected at
E13.5. Dopamine
neurogenesis was examined
by EdU intraperitoneal
injection and by assessing the
acquisition of tyrosine
hydroxylase (TH) expression.
(B) Quantification of double
EdU+;TH+ cell numbers
(mean ± SEM) for the
indicated conditions: vehicle,
24,25-EC, GGPP, and 24,25-
EC + GGPP injected
embryos. Data are means ±
SEM (n = 3-12), * P < 0.05,
** P < 0.01 by Mann-
Whitney test, compared to
vehicle group or as indicated.
(C) Microphotographs of
midbrain coronal sections
showing TH+ dopamine
neurons (green) and EdU+
cells (red) on the left panels
and higher magnification
pictures of the boxed region
on the right panels for the
indicated conditions.
Arrowheads indicate double
EdU+;TH+ cells. Scale bars,
50 µm.
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